Obeticholic acid (6-ECDCA) is a is a semi-synthetic bile acid analogue used to treat used to treat primary biliary cholangitis. Obeticholic acid is an orally available, potent and selective FXR agonist that exhibits anticholeretic and anti-inflammation effects.
orally available, potent and selective FXR agonist that exhibits anticholeretic and anti-inflammation effects
Tissue engineering and regenerative medicine, 18(2), 217-224 (2021-02-01)
Ballooned hepatocytes (BH) are a key histological hallmark of nonalcoholic steatohepatitis (NASH), yet their consequences for liver-specific functions are unknown. In our previous study, an experimental model of human induced-BHs (iBH) has been successfully developed based on cell sheet technology. This
Journal of medicinal chemistry, 45(17), 3569-3572 (2002-08-09)
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM)
Farnesoid X receptor (FXR) is a ligand-activated transcription factor involved in the control of bile acid (BA) synthesis and enterohepatic circulation. FXR can influence glucose and lipid homeostasis. Hepatic FXR activation by obeticholic acid is currently used to treat primary
Questions
Reviews
★★★★★ No rating value
Active Filters
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..